Overview

Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Status:
Unknown status

Trial end date:
2021-06-20

Target enrollment:

Participant gender:

Summary

This is a multicenter, open, randomized, comparison study. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. Neoadjuvant therapy is often used to reduce the size of tumors, especially in locally advanced tumors. The purpose of this therapy is to make part of patients operable and to facilitate breast-conserving surgery. The purpose of this study is to assess the efficacy and safety of the following two proposals: nab-paclitaxel plus carboplatin versus nab-paclitaxel plus epirubicin, in order to provide support for rational clinical application. The total number of patients to be included in this study is 520 patients.

Phase:

Phase 2

Details

Lead Sponsor:

Hebei Medical University Fourth Hospital

Collaborators:

Beijing 302 Hospital
CSPC Ouyi Pharmaceutical Co., Ltd.
The fifth medical center of PLA general hospital

Treatments:

Acivicin
Albumin-Bound Paclitaxel
Carboplatin
Epirubicin
Paclitaxel